Spero Therapeutics SPRO Cash Flow Statement (2016-2026)

NASDAQ SPRO
$1.17 -0.02 (-1.68%)
At close: Sep 9, 2026 · 4:00 PM EDT
Reported Financials

Spero Therapeutics Quarterly Cash Flow Statement

Periods 40 quarters
Latest Jun 2026

Spero Therapeutics reported cash from operations of -$5.36M and free cash flow of -$5.36M for the quarter ended Jun 2026, up 69.7% year over year. This cash flow statement covers 40 quarters of results from Sep 2016 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-22.43M-27.43M-30.14M-25.97M-11.68M26.77M-13.26M-11.91M-3.21M51.19M-12.65M-17.86M-17.73M-20.31M-13.87M-1.70M-7.38M29.93M-7.20M-9.55M
Share-based CompensationStock Comp.
8.72M2.93M8.72M8.72M10.72M2.50M11.60M11.60M11.85M2.00M2.88M2.86M2.86M1.50M2.64M2.58M2.40M1.01M21.35M21.35M
Deferred Taxes
Asset Writedowns and ImpairmentWritedown
5.31M0.60M
Cash from OperationsCash from Ops.
-4.95M-27.35M-28.22M-23.03M-0.96M44.48M-12.85M-18.56M15.91M-17.49M5.94M-18.74M12.76M-23.40M-4.00M-17.69M17.42M-8.35M15.86M-5.36M
Depreciation, Depletion & Amortization
Amortizatization of IntangiblesAmort. of Intangibles
-0.07M-0.05M-0.02M0.01M
Depreciation & Amortization (CF)Dep. & Amort.
0.15M0.19M0.19M0.29M0.26M0.13M0.11M0.11M0.11M0.04M0.00M
Change in Working Capital
Change in Account PayablesChange Payables
1.53M-2.06M3.68M-3.07M0.87M-1.97M-0.03M0.73M-0.21M0.28M1.69M-0.37M3.39M1.22M-5.54M-0.98M0.61M-0.70M-0.48M-0.06M
Change in Accured ExpensesChange Accured Exp.
0.13M5.29M-5.29M-0.55M-0.42M0.88M-0.11M-3.26M0.96M-0.01M-1.18M4.63M5.32M2.40M-9.54M-1.46M1.08M-2.23M-2.44M2.97M
Change in TaxesChange Taxes
-1.82M-0.29M0.08M-0.01M0.22M-0.22M
Other Working Capital ChangesOther WC Changes
Investing Activities
Capital ExpendituresCapex
Change in Acquisitions & DivestmentsChange Acquisitions
18.05M7.00M10.91M49.87M
Cash from Investing ActivitiesCash from Investing
17.02M-23.27M-16.06M50.00M-0.13M
Financing Activities
Other financing activitiesOther financing
0.85M48.53M0.19M0.23M0.00M
Cash from Financing ActivitiesCash from Financing
29.22M50.35M3.81M-53.68M6.13M14.18M0.22M0.00M
Change in Capital Stock
Net Shares Issued and RepurchasedNet Shares Issued
1.71M0.95M1.81M0.05M1.16M0.04M0.09M0.17M0.41M1.12M
Net Equity Issued and RepurchasedNet Equity Issued
-38.90M2.47M3.63M40.00M6.13M3.90M0.22M0.00M
Dividend Payments
Dividends Paid - CommonDiv. Paid (Common)
Additional items
Change in Cash
41.30M-0.28M-40.47M-26.71M5.04M58.66M-12.85M-18.56M16.14M-17.49M5.94M-18.74M12.76M-23.40M-4.00M-17.69M17.42M-8.35M15.86M-5.36M
Free Cash FlowFCF
-4.95M-27.35M-28.22M-23.03M-0.96M44.48M-12.85M-18.56M15.91M-17.49M5.94M-18.74M12.76M-23.40M-4.00M-17.69M17.42M-8.35M15.86M-5.36M
Net Cash FlowNCF
41.30M-0.28M-40.47M-26.71M5.04M58.66M-12.85M-18.56M16.14M-17.49M5.94M-18.74M12.76M-23.40M-4.00M-17.69M17.42M-8.35M15.86M-5.36M